ALYESKA INVESTMENT GROUP, L.P.


Item 4.A Describe your advisory firm, including how long you have been in business. Identify your principal owner(s). Alyeska Investment Group, L.P. (“Alyeska”) was founded in February 2008 and became a SEC registered investment adviser effective November 17, 2010. Alyeska provides discretionary investment advisory services to private investment funds (the “Funds” or the “Advisory Clients”).

The Funds pursue their investment strategy through two separate master-feeder fund structures. Each master-feeder structure consists of the following:

Fund One: A Delaware limited partnership (the “Domestic Feeder One”) A Cayman Islands exempted company (the “Offshore Feeder One”) A Cayman Islands exempted limited partnership (the “Master Fund One”)

Fund Two: A Delaware limited partnership (the “Domestic Feeder Two”) A Cayman Islands exempted company (the “Offshore Feeder Two”) A Cayman Islands exempted limited partnership (the “Master Fund Two”)

Fund Three: A Delaware limited partnership (the “Master Fund Three”, together with Master Fund One and Master Fund Two, the “Master Funds”) Each of the Domestic Feeders, the Offshore Feeders and the Master Funds may be referred to individually in this Brochure as a “Fund” and together as the “Funds.”

Affiliates of Alyeska, Alyeska Fund GP, LLC (the “General Partner One”), Alyeska Fund 2 GP, LLC (the “General Partner Two”), and Alyeska Fund 3 GP, LLC (the “General Partner Three”, together with the General Partner One and General Partner Two, the “General Partners”), serve as the general partners of the Domestic Feeder One, Master Fund One, Domestic Feeder Two, Master Fund Two, and Master Fund Three, respectively. Each General Partner is governed by a Board of Managers (the “Board of Managers”). Principals of Alyeska serve as members of the Board of Managers.

Anand Parekh is the principal owner of Alyeska. Alyeska Investment Group, LLC is the sole owner of the General Partner One, the General Partner Two and the General Partner Three. Anand Parekh is the managing member of Alyeska Investment Group, LLC. specializing in a particular type of advisory service, such as financial planning, quantitative analysis, or market timing, explain the nature of that service in greater detail. If you provide investment advice only with respect to limited types of investments, explain the type of investment advice you offer, and disclose that your advice is limited to those types of investments. Alyeska has broad and flexible investment authority. Alyeska offers advice on both long and short positions in a wide range of investment products, including equity, equity-linked, credit and credit-linked instruments. The actual instruments traded generally include stocks, corporate bonds, convertible bonds, options, futures, credit and equity derivatives, and other credit-based instruments. Such instruments are traded on public exchanges or in private over-the-counter (“OTC”) transactions. Alyeska seeks to mitigate systematic risk embedded in equity securities through the deliberate construction of non-systematic portfolios. Advisory Clients enter into various contracts or positions to further mitigate unwanted exposures. To reduce interest rate and/or currency risk, and subject to certain regulatory thresholds applicable to pools relying on Commodity Futures Trading Commission (“CFTC”) Regulation 4.13(a)(3), Advisory Clients enter into long or short positions in interest rate derivatives government securities (and derivatives thereon) and/or foreign currency spot and forward contracts. In connection with certain transactions involving convertible bonds and capital structure arbitrage, the Advisory Clients at times enter into credit default swap contracts. Advisory Clients buy or sell equity index contracts as specific or portfolio hedges. Derivatives contracts may be exchange-traded or OTC. Advisory Clients also retain amounts in cash or cash equivalents, pending reinvestment.

While the above describes the main financial instruments on which Alyeska offers advice, it is not meant to preclude Alyeska from using other financial instruments not described above.

Advisory Clients, to the extent permitted by the rules of the Financial Industry Regulatory Authority (“FINRA Rules”), purchase equity securities that are part of an initial public offering (sometimes referred to as “IPOs” or “New Issues”) when such opportunity is deemed appropriate for the Advisory Clients. Any investments in New Issues are equitably allocated amongst investors based on their restricted/unrestricted status consistent with the mandates of the FINRA Rules.

Fund One is managed largely in parallel with Fund Two, except that Fund Two generally targets a leverage ratio that is approximately 1.5 times greater than Fund One, and a corresponding risk that is approximately 1.5 times greater than Fund One. Fund Three is managed largely in parallel with Fund One, except that Fund Three incorporates additional exposures from certain broad market indices and the risks associated therewith. individual needs of clients. Explain whether clients may impose restrictions on investing in certain securities or types of securities.

Alyeska does not tailor its advisory services to the individual needs of investors in the Funds (“Investors”), nor may Investors impose restrictions on investing in certain securities or types of securities. services, (1) describe the differences, if any, between how you manage wrap fee accounts and how you manage other accounts, and (2) explain that you receive a portion of the wrap fee for your services. Alyeska does not participate in wrap fee programs. discretionary basis and the amount of client assets you manage on a non- discretionary basis. Disclose the date “as of” which you calculated the amounts. As of December 31, 2019, Alyeska manages approximately $10,422,021,022 of Advisory Client regulatory assets under management on a discretionary basis. Alyeska does not currently manage any Advisory Client assets on a non- discretionary basis. please register to get more info

Open Brochure from SEC website

Related news

Recro Pharma (NASDAQ:REPH) Stock Price Up 8.4%

Recro Pharma, Inc. (NASDAQ:REPH)’s stock price rose 8.4% on Monday . The stock traded as high as $3.12 and last traded at $3.09. Approximately 1,047,411 shares were traded during mid-day trading, an increase of 90% from the average daily volume of 552,

$3.76 Billion in Sales Expected for Fiserv, Inc. (NASDAQ:FISV) This Quarter

Brokerages expect Fiserv, Inc. (NASDAQ:FISV) to report sales of $3.76 billion for the current fiscal quarter, Zacks reports. Eleven analysts have made estimates for Fiserv’s earnings, with estimates ranging from $3.

$22.01 Million in Sales Expected for Evolus, Inc. (NASDAQ:EOLS) This Quarter

Brokerages forecast that Evolus, Inc. (NASDAQ:EOLS) will post $22.01 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Evolus’ earnings,

MeiraGTx Holdings PLC

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Insider Buys CC Neuberger Principal's Shares

A Form 4 filing filed with the SEC on Thursday, December 17 showed that Alyeska Investment Group, L.P. bought 34,800 shares of CC Neuberger Principal Inc (NYSE:PCPL) at an average price of $10.29.

Where Do Hedge Funds Stand On Tenaris S.A. (TS)?

Anand Parekh’s fund, Alyeska Investment Group, also cut its stock, about $11.1 million worth. These transactions are interesting, as aggregate hedge fund interest stayed the same (this is a ...

Where Do Hedge Funds Stand On OrthoPediatrics Corp. (KIDS)?

So, let’s review which hedge funds were among the top holders of ... s Burrage Capital Management and Anand Parekh’s Alyeska Investment Group. In terms of the portfolio weights assigned ...

The Manufacturers Life Insurance Company Acquires Shares of 8,635 Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX)

The Manufacturers Life Insurance Company acquired a new stake in shares of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).

The Manufacturers Life Insurance Company Decreases Holdings in First BanCorp. (NYSE:FBP)

The Manufacturers Life Insurance Company trimmed its holdings in shares of First BanCorp. (NYSE:FBP) by 3.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission.

Swiss National Bank Boosts Stock Position in Under Armour, Inc. (NYSE:UAA)

Swiss National Bank lifted its holdings in shares of Under Armour, Inc. (NYSE:UAA) by 0.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 427,100 shares of the company’s stock after purchasing an additional 2,
Loading...
No recent news were found.